title: Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.
abstract: The serine/threonine protein kinase, TBK1, plays a crucial role as the hub for many innate immune signaling pathways that lead to the induction of type I interferon (IFN) and interferon-stimulated genes (ISGs). Due to its key function in maintaining homeostasis of the immune system, cell survival and proliferation, TBK1 activity is tightly regulated. Dysregulation of TBK1 activity is often associated with autoimmune diseases and cancer, implicating the potential therapeutic benefit for targeting TBK1. Tremendous effort from both academic institutions and private sectors during the past few years has led to the development of many potent and selective TBK1 inhibitors, many of which have shown great promise in disease models in vivo. This review summarizes recent advance on the pharmacological inhibition of TBK1 and its potential for treating autoimmune diseases and interferonopathies.
authors.affiliation: Autoimmunity, Transplantation and Inflammation, Novartis Institute of Biomedical Research, CH?4056 Basel, Switzerland. Electronic address: Maroof.Hasan@novartis.com.
authors.forename: Maroof
authors.initials: M
authors.lastname: Hasan
authors.affiliation: Departments of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA; Departments of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: Nan.Yan@utsouthwestern.edu.
authors.forename: Nan
authors.initials: N
authors.lastname: Yan
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D015551:Autoimmunity / Q000187:drug effects*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D007372:Interferons / Q000276:immunology / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D007155:Immunologic Factors; D047428:Protein Kinase Inhibitors; D007372:Interferons; D017346:Protein Serine-Threonine Kinases; C403191:TBK1 protein, human
keywords: Autoimmune disease; Interferonopathy; Lupus; TBK1; Type I interferon